Palbociclib (PD-0332991) HCl

Licensed by Pfizer 製品コードS1116

Palbociclib (PD-0332991) HCl化学構造

分子量(MW):483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

サイズ 価格(税別)  
JPY 18260.00
JPY 28220.00
JPY 94620.00

カスタマーフィードバック(8)

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  •  

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

    WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

    P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

製品安全説明書

CDK阻害剤の選択性比較

生物活性

製品説明 Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
特性 Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
ターゲット
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
体外試験

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 Mlf6T4lv[XOnIFHzd4F6 MXuyOEBp NIf1T4xKdmirYnn0bY9vKG:oIFPET|Qh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFAzKM7:TR?= NGfNdFEzPDZ2MUGwNy=>
COLO205 NVPtZWpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3VXI44OiCq M1rHSWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yM{[g{txO NFf2bW8zPDZ2MUGwNy=>
U937 M2\iOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfqO|IhcA>? MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvOTRizszN M1HQe|I1PjRzMUCz
MOLM13 M4Xvbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWe3NkBp NUGwbo1HSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHHueEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? MUiyOFY1OTFyMx?=
MOLM13 NXP1RZBYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHMUJk4OiCq MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO NFfzeXIzPDZ2MUGwNy=>
MDA-MB-435 M{XGSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjWdWd4OjRiaB?= Mnm0TWM2OD1yLkG2JO69VQ>? MWexOVgxOTh|MR?=
K562 MliwR5l1d3SxeHnjJGF{e2G7 NFPPOGo6PiCq NH3NNXVFVVOR MWLJR|UxRTJizszN NUjRfphnOjR2MUe1OlY>
DU145 M3nndmN6fG:2b4jpZ{BCe3OjeR?= MWK5OkBp M{jLOWROW09? MnPMTWM2OD15LkWg{txO M3rRPFI1PDF5NU[2
MDA-MB-231 MlmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rpZ|Eh|ryP MorTNlQhcA>? MoXOSG1UVw>? MnLpR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl NHSzOokzPDRzN{W2Oi=>
MCF7 NInLbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzCNUDPxE1? M4nzTFI1KGh? MkKySG1UVw>? NEXFfVZE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> NYCzU2hNOjR2MUe1OlY>
MCF7 NU\NO2lTU2mwYYPlJGF{e2G7 M{DEXFUh|ryP MnrCNlQhcA>? NE\ae29FVVOR NXewcno5UW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> M1PFe|I1PDF5NU[2
MDA-MB-231 M1:yVWtqdmG|ZTDBd5NigQ>? MlO5OUDPxE1? M3vVPVI1KGh? M3\WRWROW09? NXvpOooxUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> NHnTcJMzPDRzN{W2Oi=>
MDA-MB-231 NFPVS5dHfW6ldHnvckBCe3OjeR?= MorrNU0yOCEQvF2= M1\GOlI1KGh? NGHCVGtFVVOR NVPOR2RG\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppd{Bie3Onc4Pl[EBieyCSQWLQJINt\WG4YXfl MVyyOFQyPzV4Nh?=
MCF7 MnPMSpVv[3Srb36gRZN{[Xl? NWPTOGVyOS1zMDFOwG0> M1j5e|I1KGh? MUnEUXNQ MnnE[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BRSVKSIHPs[YF3[Wen NUDh[YpOOjR2MUe1OlY>
MDA-MB-231 M4S2OmZ2dmO2aX;uJGF{e2G7 NIDDeVExNjVvMTFOwG0> NXXqbVRyPDhiaB?= NID5c2RFVVOR NHjxdpRp[XNibn:gR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JJN2[i2JMTDwbIF{\Q>? Ml:0NlQ1OTd3Nk[=
MCF7 M1HsWmZ2dmO2aX;uJGF{e2G7 M1z1RVAvPS1zIN88US=> M3S1bFQ5KGh? NH;n[VlFVVOR NUi1NHhFcGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V? Mm\XNlQ1OTd3Nk[=
697 NEW2OohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHISWNsUUN3ME2xOFgvOzhibl2= M17xWnNCVkeHUh?=
P12-ICHIKAWA M4\4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTl4LkC0JI5O NF\VT4JUSU6JRWK=
NB69 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7UTWM2OD1zNkGuPEBvVQ>? MlXXV2FPT0WU
EoL-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTF6Nz6yOkBvVQ>? NIT5O4RUSU6JRWK=
BHT-101 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H0NmlEPTB;MUm4MlI2KG6P MoK5V2FPT0WU
SK-NEP-1 M2XSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj3cYU{UUN3ME2yNlAvODJibl2= M{fDUXNCVkeHUh?=
MHH-NB-11 Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHrTWM2OD1{MkCuNVkhdk1? MVzTRW5ITVJ?
AsPC-1 NFfVR21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTJ3Mj61N{BvVQ>? NFPQTppUSU6JRWK=
ES1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPBbFFKSzVyPUK1Ok4zPSCwTR?= NH\BeJBUSU6JRWK=
LAMA-84 NUexW|UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTJ3OD6xPUBvVQ>? NVfGfnBzW0GQR1XS
MOLT-16 NHn1VHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD5TYFlUUN3ME2yOVgvPDlibl2= NYH3eXFUW0GQR1XS
ES7 M2f0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCxSJJrUUN3ME2yO|MvODlibl2= MmjBV2FPT0WU
KY821 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Lrc2lEPTB;M{G0MlEhdk1? M2S1OHNCVkeHUh?=
RT-112 M1noemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PHWWlEPTB;M{KxMlA2KG6P MU\TRW5ITVJ?
HL-60 MmjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnES3pKSzVyPUO0NE43PiCwTR?= MXzTRW5ITVJ?
MOLT-4 NFjMOZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\lUnhKSzVyPUO0OU4yOyCwTR?= M{LnOnNCVkeHUh?=
KARPAS-45 M3y5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTN5Nj6xOkBvVQ>? NUD6SphbW0GQR1XS
SK-N-AS NUeyTZlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDPVGltUUN3ME2zPFcvQDNibl2= MoG0V2FPT0WU
CTB-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jwS2lEPTB;NEC1MlAzKG6P Mn;aV2FPT0WU
NKM-1 M{Hncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH33V3RKSzVyPUSxNU45QSCwTR?= NILndIZUSU6JRWK=
HTC-C3 NXTPfIN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULJe4s6UUN3ME20N|IvQTVibl2= NF61OlRUSU6JRWK=
BE-13 NHXIWFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFu3VndKSzVyPUS0OE4zPyCwTR?= MlTSV2FPT0WU
KOSC-2 NE\kRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTkTWM2OD12Nk[uPUBvVQ>? NUOxNYg4W0GQR1XS
NB14 NV7Wd41xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzmbYRKSzVyPUS4N{42QCCwTR?= Ml31V2FPT0WU
CAL-27 M{[1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLJWXBKSzVyPUS5OE42QSCwTR?= Mo\qV2FPT0WU
H9 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInycXhKSzVyPUS5OU41OyCwTR?= MV;TRW5ITVJ?
RS4-11 NFntcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHQT4NtUUN3ME21NFQvPzNibl2= M4izOnNCVkeHUh?=
PA-1 MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDLUoVKSzVyPUWwPU45PiCwTR?= MkTRV2FPT0WU
MV-4-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfiWmZxUUN3ME21NVMvQDVibl2= NFfyTotUSU6JRWK=
OS-RC-2 MliwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nnTmlEPTB;NUKxMlYzKG6P MXXTRW5ITVJ?
RPMI-8226 NXn5dZB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj2TWM2OD13Mk[uPFYhdk1? MmHIV2FPT0WU
HGC-27 NXPBSJdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXaWHFEUUN3ME21OlQvQTlibl2= NYLL[nl[W0GQR1XS
CHP-212 M3TjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTV7Mz61PUBvVQ>? MlK2V2FPT0WU
NB10 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj0WIRKSzVyPUW5PU4yQCCwTR?= MWPTRW5ITVJ?
HH NWTmfINiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWnVbJhMUUN3ME21PVkvPDNibl2= MXfTRW5ITVJ?
EW-16 NXW0e2RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTZyMz61NkBvVQ>? NHLMU2hUSU6JRWK=
ES8 NYO2Xmo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofoTWM2OD14MEWuNlEhdk1? M4TBenNCVkeHUh?=
HAL-01 MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfIXmlnUUN3ME22NFUvPjdibl2= MV7TRW5ITVJ?
A204 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZ|Mz65NUBvVQ>? NFPISVVUSU6JRWK=
MHH-PREB-1 MnXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnBN3FRUUN3ME22N|YvQTlibl2= MoqwV2FPT0WU
EM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PWR2lEPTB;NkWwMlY1KG6P NHTN[GZUSU6JRWK=
BV-173 Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTZ3Mj60PEBvVQ>? NFHoVVdUSU6JRWK=
ONS-76 NIOxeHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTZ5Nz64NkBvVQ>? Mn\XV2FPT0WU
KM-H2 M{G4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HHVGlEPTB;Nkm1MlU1KG6P MonZV2FPT0WU
D-263MG MnPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTWTWM2OD15MUeuNVIhdk1? NETiVHhUSU6JRWK=
ES3 NUnTUopvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID0eYNKSzVyPUeyPE46OyCwTR?= MmXGV2FPT0WU
VA-ES-BJ M1;OeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTd|Mj6yO{BvVQ>? NX\OT3NKW0GQR1XS
NBsusSR NFfEV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXpTWM2OD15NEKuPVkhdk1? MYPTRW5ITVJ?
NCI-H520 M4DJdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLxTWM2OD15NE[uOVIhdk1? NEDPbWFUSU6JRWK=
ES5 Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnKTWM2OD15NUKuPEBvVQ>? MXrTRW5ITVJ?
T-24 M2TpeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn3V4ZKSzVyPUe3PE44OSCwTR?= NEPiO5hUSU6JRWK=
SW962 NH\JWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TOcGlEPTB;OEC4MlY{KG6P NVLaPJd4W0GQR1XS
EW-3 M4f3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFu2fnpKSzVyPUiwPE44PiCwTR?= NYXC[WNPW0GQR1XS
RXF393 Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVKzRpd{UUN3ME24NVIvPzlibl2= MYLTRW5ITVJ?
U251 NUXaTGlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEH6PG1KSzVyPUixN{45QCCwTR?= NUCy[3F7W0GQR1XS
CAMA-1 NHTjcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGruT3NKSzVyPUizN{46PCCwTR?= MWXTRW5ITVJ?
JVM-3 MnfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn3TWM2OD16NUGuO|ghdk1? M3j2[nNCVkeHUh?=
COLO-800 M4WwcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHpTWM2OD16OUeuO|ghdk1? MUjTRW5ITVJ?
OVCAR-5 M3e2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTlyMD6xJI5O M2nYRnNCVkeHUh?=
LB1047-RCC NEjSWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXhN3VKSzVyPUmyO{42PiCwTR?= MXnTRW5ITVJ?
SW954 M1[0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfnSo8xUUN3ME25NlkvPDFibl2= NVX4d5duW0GQR1XS
J-RT3-T3-5 NUX3PXZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEX4OnVKSzVyPUmzOk4xPiCwTR?= MVTTRW5ITVJ?
Mewo NV6yXodPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXKeox4UUN3ME25N|YvPiCwTR?= NGHjSoVUSU6JRWK=
NCI-H1770 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEG0R4FKSzVyPUm0NE42PSCwTR?= NXv2O48zW0GQR1XS
HO-1-N-1 NHzTTY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHf3XoZKSzVyPUm2Nk45OSCwTR?= NELHTJpUSU6JRWK=
HSC-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf5eWZpUUN3ME25OlYvPDhibl2= MmLzV2FPT0WU
TYK-nu NEPNPJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTl7OD6yOUBvVQ>? M3viXHNCVkeHUh?=
KYSE-150 M1i2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnZSHFKSzVyPUGuNFAxPzZizszN MV;TRW5ITVJ?
SN12C NVj2SHdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnETWM2OD1zLkCwPFc2KM7:TR?= MVTTRW5ITVJ?
MOLT-13 NGTkPY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFwMEG0NlEh|ryP MmT4V2FPT0WU
TE-11 MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml:yTWM2OD1zLkC0PFEzKM7:TR?= NXTBN2ZSW0GQR1XS
DB M2rUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXqTWM2OD1zLkC3Nlc{KM7:TR?= NYiy[FMxW0GQR1XS
CAL-39 NX;Rco17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTFwMEe1NlIh|ryP NIHESXZUSU6JRWK=
A3-KAW M3rnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTFTWM2OD1zLkC4OFA5KM7:TR?= NWXYfIN1W0GQR1XS
CHP-134 Mmf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVr0[JZnUUN3ME2xMlEyQDB5IN88US=> MUPTRW5ITVJ?
TGW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{S5V2lEPTB;MT6xNlM6PSEQvF2= NEnQN49USU6JRWK=
QIMR-WIL NGnaUpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\2WWlEPTB;MT6xN|E{PCEQvF2= NH\B[HhUSU6JRWK=
NCI-SNU-1 NHT6dplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFwMU[zOVQh|ryP NXzqNppoW0GQR1XS
CGTH-W-1 M4DiOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CxcWlEPTB;MT6xO|E5PiEQvF2= NEHvRoJUSU6JRWK=
MHH-ES-1 MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vxO2lEPTB;MT6xO|k5PiEQvF2= M{DicnNCVkeHUh?=
LB2241-RCC MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvNUnNKSzVyPUGuNVg3OiEQvF2= NXTMSnp7W0GQR1XS
ML-2 M4j2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;YTWM2OD1zLkKwO|M1KM7:TR?= MXLTRW5ITVJ?
COR-L23 NXnxTZA{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPaTWM2OD1zLkKyPVM{KM7:TR?= NGnQNGFUSU6JRWK=
BFTC-905 M33pPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nzV2lEPTB;MT6yOFI3PyEQvF2= NHTuUpZUSU6JRWK=
Hs-578-T NXS5UZdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTFwMkW4NVch|ryP Mn33V2FPT0WU
KG-1 NF[ydm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PK[mlEPTB;MT6yOlY5PiEQvF2= M4fNZ3NCVkeHUh?=
HEL M4\acWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTQTWM2OD1zLkK5N|M5KM7:TR?= NVXXTVF6W0GQR1XS
A549 M1HYfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknZTWM2OD1zLkK5N|k6KM7:TR?= NWLjSmtrW0GQR1XS
COLO-741 NX7PcVhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPxUnZ6UUN3ME2xMlMzODh7IN88US=> M2L2N3NCVkeHUh?=
PC-3 NHjOT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLCbWpEUUN3ME2xMlM2OjJzIN88US=> NEHSWGhUSU6JRWK=
HOS NF;NNm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFwM{WyPVYh|ryP MWfTRW5ITVJ?
HT-1080 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED1TXpKSzVyPUGuN|c2OTlizszN MkjEV2FPT0WU
TE-8 M1zkdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTFwNEG3O|Qh|ryP M3S3bXNCVkeHUh?=
BHY MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M135O2lEPTB;MT60OlkzOyEQvF2= M4fpNnNCVkeHUh?=
BB65-RCC M{PYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3rWXZQUUN3ME2xMlUxPTJ6IN88US=> MVTTRW5ITVJ?
HN NXrWUYg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnZSYY1UUN3ME2xMlU1ODdzIN88US=> MV3TRW5ITVJ?
NCI-H441 NI\oNohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYe1NnZ7UUN3ME2xMlU1QTB5IN88US=> NXfpdXFkW0GQR1XS
RPMI-8866 MknvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTZTWM2OD1zLkW4OVA4KM7:TR?= NUXtUI5DW0GQR1XS
CAL-62 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\1TWM2OD1zLk[wPFYzKM7:TR?= M{jCcnNCVkeHUh?=
MG-63 MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq0TWM2OD1zLk[xPFE{KM7:TR?= Mn\GV2FPT0WU
SK-LU-1 MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\kd2hKSzVyPUGuOlIyPTJizszN MUTTRW5ITVJ?
BCPAP MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjVb45KSzVyPUGuOlY1PTdizszN MYLTRW5ITVJ?
22RV1 NWXrWJNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTlTWM2OD1zLk[3PFQ{KM7:TR?= MmLyV2FPT0WU
T47D NEjmWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz4TZJkUUN3ME2xMlY5ODZzIN88US=> NFnLdFdUSU6JRWK=
MSTO-211H MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi3bXR7UUN3ME2xMlY6PjB|IN88US=> MkHEV2FPT0WU
DEL MoDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe4e4JKSzVyPUGuO|AzPzNizszN NETxOoNUSU6JRWK=
H4 M4P1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm1TWM2OD1zLkezNlEzKM7:TR?= MUTTRW5ITVJ?
CAL-51 NUW4cmFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK2eHhYUUN3ME2xMlc1QDV3IN88US=> NHjQ[plUSU6JRWK=
ABC-1 NXTyO4ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjqfXdyUUN3ME2xMlc5PTh{IN88US=> NVjwSZltW0GQR1XS
MZ2-MEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjPdnRxUUN3ME2xMlc6PTR{IN88US=> M{nN[3NCVkeHUh?=
YKG-1 NXnYW4xRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFwOEGwOlEh|ryP MYLTRW5ITVJ?
KM12 NELPT|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT3TWM2OD1zLkixOlAzKM7:TR?= NWnKXXp7W0GQR1XS
L-363 MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwOEe0NVIh|ryP Mn7uV2FPT0WU
KU812 NH3DZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:4TlVKSzVyPUGuPFkzQDJizszN NEXT[odUSU6JRWK=
LOXIMVI NW\LVVhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwOUGyNlgh|ryP NXv5NVd5W0GQR1XS
G-401 NFnR[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwOUK0Nlgh|ryP MorRV2FPT0WU
SW780 MnmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LxXGlEPTB;MT65OlI1PiEQvF2= Mo\kV2FPT0WU
SW872 NWnGV|A2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVL4dpZxUUN3ME2xMlk5OzNizszN NUniOpF6W0GQR1XS
NB7 NHLXd2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPVT2xKSzVyPUGuPVk{OjNizszN MUTTRW5ITVJ?
T98G NH3N[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1[0e2lEPTB;Mj6wNFY3PiEQvF2= M1:0SXNCVkeHUh?=
SW1710 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHaRXpKSzVyPUKuNFY6PDVizszN NGLufG9USU6JRWK=
NCI-H1573 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW4S3hKSzVyPUKuNFczQThizszN Ml\oV2FPT0WU
KE-37 MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJwMEi5OVEh|ryP NFPLNZFUSU6JRWK=
786-0 NGr2SIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVe2NnlxUUN3ME2yMlE2PDN7IN88US=> MVLTRW5ITVJ?
SAS NVrqU|ljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJwMkCzO|Qh|ryP NIH0VYdUSU6JRWK=
CAL-54 NVOyZohmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH3cZJtUUN3ME2yMlIxPDF|IN88US=> M4fFOXNCVkeHUh?=
SF268 NGnkW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrtOo5RUUN3ME2yMlI{OTJ{IN88US=> M4r1b3NCVkeHUh?=
SW620 M2i0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4izTmlEPTB;Mj6yOlE3QSEQvF2= NIC2Z3dUSU6JRWK=
MN-60 NVK0WWxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvZ[21KSzVyPUKuN|ExPiEQvF2= MYjTRW5ITVJ?
EFO-27 NVTjRW5wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TqemlEPTB;Mj6zNlA2QCEQvF2= M3f1SXNCVkeHUh?=
NCI-H747 NULTWmZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJwM{KxPVkh|ryP M4\OT3NCVkeHUh?=
HCC2218 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfVWZJXUUN3ME2yMlM2Ozd2IN88US=> MVfTRW5ITVJ?
MIA-PaCa-2 MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rxXmlEPTB;Mj6zOlQ{PyEQvF2= Mk\VV2FPT0WU
SJSA-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJwM{e3PVYh|ryP NYDLUZNrW0GQR1XS
RKO NHzRN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TVUWlEPTB;Mj6zPFQ6PiEQvF2= NILPXlZUSU6JRWK=
NB6 NH\hSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3Nc2NiUUN3ME2yMlQxOzd2IN88US=> MlTMV2FPT0WU
ES4 MnTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJwNEW0NlIh|ryP MYLTRW5ITVJ?
EGI-1 MoXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTJwNE[4PFMh|ryP MnrWV2FPT0WU
CTV-1 MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\IXVJqUUN3ME2yMlUzPzd|IN88US=> NH7jVXpUSU6JRWK=
NCI-H1355 MlLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3exXGlEPTB;Mj61OVk2OSEQvF2= NGK2T4xUSU6JRWK=
GT3TKB MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HYUmlEPTB;Mj61PVE6QSEQvF2= MnzDV2FPT0WU
SK-HEP-1 Mkf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTJwNUmyOlYh|ryP NVy5d3BrW0GQR1XS
GAMG MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnixTWM2OD1{LkW5N|k1KM7:TR?= NWK0N3pSW0GQR1XS
SK-MES-1 M{H5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP6S2RKSzVyPUKuOlE5ODNizszN MmXMV2FPT0WU
RO82-W-1 NFvsPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJwNkKwOVch|ryP NFriTWhUSU6JRWK=
ECC10 NVn5WVVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP6bIVmUUN3ME2yMlcxOjB4IN88US=> NW\4PGFiW0GQR1XS
MCF7 Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILLbm9KSzVyPUKuO|E1PjRizszN MkHNV2FPT0WU
D-283MED M3fJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrtNXJKSzVyPUKuO|I1OyEQvF2= NIjhTlVUSU6JRWK=
RPMI-7951 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK4e5RKSzVyPUKuO|U3QTRizszN M{XXV3NCVkeHUh?=
Ramos-2G6-4C10 NI\C[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4OxbWlEPTB;Mj63O|A6QSEQvF2= MXHTRW5ITVJ?
KGN MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz5W|JKSzVyPUKuPFE5QDRizszN NYDTfZZJW0GQR1XS
NUGC-3 MnrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrjTHpKSzVyPUKuPFI2ODVizszN M3ny[HNCVkeHUh?=
NCI-H292 NFnPdo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nkRmlEPTB;Mj64OVA2OyEQvF2= NX;DRokxW0GQR1XS
Becker MnmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2G5[WlEPTB;Mj65OVg{OiEQvF2= MljXV2FPT0WU
NCI-H1299 NX;NcHJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVK4THFFUUN3ME2zMlA2OjZ|IN88US=> M{\6bXNCVkeHUh?=
ETK-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG2TWM2OD1|LkC1OFMh|ryP NUe4dpd[W0GQR1XS
TK10 MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTBTWM2OD1|LkKwNVY2KM7:TR?= NXL3dWc{W0GQR1XS
VMRC-RCZ MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojITWM2OD1|LkO2OFg5KM7:TR?= MkXmV2FPT0WU
YH-13 NFjtcWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNwNESwO|kh|ryP MYjTRW5ITVJ?
DU-145 NG\lc21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TNOmlEPTB;Mz60OlI3QSEQvF2= Mn;iV2FPT0WU
SW1088 NYjaUGN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETmZ5JKSzVyPUOuOFc1PyEQvF2= NW\qOnZXW0GQR1XS
HOP-92 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXGTo9KSzVyPUOuOVA{PDJizszN M1LMeXNCVkeHUh?=
KP-N-YS M1jUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7JZ25yUUN3ME2zMlYzOTN7IN88US=> MlnZV2FPT0WU
NCI-H460 NXLnUZR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTNwNk[3N{DPxE1? M4G1VnNCVkeHUh?=
U-2-OS M{nQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrjfZNKSzVyPUOuO|I2OzVizszN MXTTRW5ITVJ?
A101D NVK0N2lHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHoRm9KSzVyPUOuO|Y6OzZizszN NXjIcW5qW0GQR1XS
MDA-MB-231 NEXTdJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn5TWM2OD1|LkixPVUyKM7:TR?= MkfqV2FPT0WU
IST-MES1 NYD5OJE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfKTWM2OD1|LkizNkDPxE1? NVi0NYt{W0GQR1XS
COR-L105 NX3YdlJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\UU4lKSzVyPUSuNFE5KM7:TR?= NXm1U45oW0GQR1XS
NCI-H1437 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXTOXdIUUN3ME20MlAzOzB{IN88US=> M1nlXnNCVkeHUh?=
CAL-85-1 NWPGT|dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHGUlVKSzVyPUSuNFI1PjFizszN MkHKV2FPT0WU
MZ1-PC MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTRwMUi1OVYh|ryP NVqyPYtuW0GQR1XS
VM-CUB-1 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVG5OnVmUUN3ME20MlMyOjh2IN88US=> MUHTRW5ITVJ?
CHL-1 NEnQOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7LTWM2OD12LkOyNVY6KM7:TR?= NHXNUlJUSU6JRWK=
MDA-MB-361 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITzT45KSzVyPUSuN|MyPTNizszN MWjTRW5ITVJ?
NCI-H661 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETzS3dKSzVyPUSuOVAxQTJizszN MYDTRW5ITVJ?
EW-11 NEjVVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTRwNUKyN|Eh|ryP MY\TRW5ITVJ?
BEN M1KyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFznXldKSzVyPUSuOVI5OTVizszN MWjTRW5ITVJ?
BFTC-909 Ml3jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnyfnFKSzVyPUSuOVYzPzVizszN MYrTRW5ITVJ?
NCI-H2087 M3z4cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLUTWM2OD12LkW4NVY1KM7:TR?= NH;lfZVUSU6JRWK=
RVH-421 NHjwcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoP3TWM2OD12Lk[2Olkh|ryP M3GwUnNCVkeHUh?=
P30-OHK MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HkfWlEPTB;ND62PFAxQCEQvF2= NHLWWVZUSU6JRWK=
NCI-H28 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfuUJN{UUN3ME20MlgyPjZzIN88US=> MmGzV2FPT0WU
ES6 M3vDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1[4fWlEPTB;ND64N|AyPiEQvF2= NFTNOlRUSU6JRWK=
769-P NWD3ZpFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP6fYdEUUN3ME20Mlg2QTJ4IN88US=> M3LYcnNCVkeHUh?=
OE33 NULxbIFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\GZ3RHUUN3ME20Mlg5OTZzIN88US=> MWDTRW5ITVJ?
SW982 MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LZ[mlEPTB;ND65OVA3OSEQvF2= M2XkTnNCVkeHUh?=
A388 MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTVwMEK5PFMh|ryP NE\yTmhUSU6JRWK=
TI-73 M4Tre2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHlT3BKSzVyPUWuNFYyQTRizszN NVzmTWhzW0GQR1XS
HCT-116 NYD5SWR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPOTWM2OD13LkC5PFg6KM7:TR?= MoHmV2FPT0WU
HuP-T3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLYemJTUUN3ME21MlE5PzB7IN88US=> NXrBPZN6W0GQR1XS
G-402 NWHUbVlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rLZWlEPTB;NT6xPVQyPiEQvF2= M{nhcnNCVkeHUh?=
NCI-H1792 M{\ybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHlcHplUUN3ME21MlI1PjJ{IN88US=> M3exT3NCVkeHUh?=
NCI-H209 NVHo[mdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7JTWM2OD13LkK1PVQzKM7:TR?= NIizOGhUSU6JRWK=
NCI-H1650 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTVwM{C2N|Qh|ryP M3PFSHNCVkeHUh?=
LCLC-97TM1 NFLtcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXXTWM2OD13LkOxPFA5KM7:TR?= MkLpV2FPT0WU
S-117 NXfMZ404T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnKTWM2OD13LkO2PVc3KM7:TR?= MoLEV2FPT0WU
GI-ME-N NGTCUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTVwM{m2PFEh|ryP M{jsPXNCVkeHUh?=
NCI-H2122 NHH0TllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe1cnJ3UUN3ME21MlQ6Ozl5IN88US=> MVzTRW5ITVJ?
NCI-H1793 NFrBcoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTVwNke1PVMh|ryP NYXJSol3W0GQR1XS
C2BBe1 M1noR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnjTWM2OD13LkewNFg5KM7:TR?= NHP5O3NUSU6JRWK=
TE-12 M3rKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTVwOEC1OVYh|ryP M4[zXHNCVkeHUh?=
LCLC-103H NIHRfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTVwOUG3JO69VQ>? MnX5V2FPT0WU
A673 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXLTWM2OD13LkmxPVMzKM7:TR?= NGC3fpVUSU6JRWK=
BB30-HNC NEfIXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D3WmlEPTB;NT65PFM3KM7:TR?= NVe3V4x5W0GQR1XS
SF295 M4rFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTZwMEC0NlIh|ryP NYXQUZZ5W0GQR1XS
KU-19-19 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fLVmlEPTB;Nj6wNVc{OSEQvF2= MV\TRW5ITVJ?
CFPAC-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofOTWM2OD14LkC0OFQ{KM7:TR?= NYjmXlFRW0GQR1XS
LoVo MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTZwMEWwOlMh|ryP NFnENZlUSU6JRWK=
8505C MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rjSmlEPTB;Nj6wO|U4OyEQvF2= MX\TRW5ITVJ?
GMS-10 MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHTv[5JKSzVyPU[uNVUxODJizszN MV\TRW5ITVJ?
Ca9-22 NYTEeIdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjxSWZKSzVyPU[uNVY4OSEQvF2= MVvTRW5ITVJ?
DOK M2GyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTZwMkKwO|Ih|ryP MX3TRW5ITVJ?
FADU M{j2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi3NWJsUUN3ME22MlI3ODN7IN88US=> MXvTRW5ITVJ?
BxPC-3 NYn6V5g3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPqTWM2OD14LkK3N|Ih|ryP M3n4R3NCVkeHUh?=
CAL-33 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorGTWM2OD14LkK5NlAyKM7:TR?= NHHSW5dUSU6JRWK=
SHP-77 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XCemlEPTB;Nj6zNVUyOiEQvF2= M2DNNnNCVkeHUh?=
LXF-289 NVjqc4NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml34TWM2OD14LkOzOFU2KM7:TR?= NXrkO4V3W0GQR1XS
GB-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvyTWxKSzVyPU[uN|gzKM7:TR?= NWe1fGJpW0GQR1XS
KS-1 NYXJZ5g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjnfZY1UUN3ME22MlM5PDR5IN88US=> MXjTRW5ITVJ?
D-502MG MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXkdIpKSzVyPU[uOFI{PzZizszN M3zIdXNCVkeHUh?=
LAN-6 NEPY[2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\y[2dYUUN3ME22MlUyODJ|IN88US=> M{LBTXNCVkeHUh?=
H-EMC-SS M{GyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPzTWM2OD14LkW2NVQ4KM7:TR?= MUjTRW5ITVJ?
LC-2-ad NIO1[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLuZpBKSzVyPU[uOlAxPzZizszN NXPuXVdxW0GQR1XS
NCI-H1693 MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M132cGlEPTB;Nj62NlIyPSEQvF2= NGXETmFUSU6JRWK=
SK-N-FI M13Mdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLPSmpbUUN3ME22Mlc2ODR2IN88US=> MV\TRW5ITVJ?
D-423MG MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzHUlQxUUN3ME22Mlc3OTF5IN88US=> M1juOnNCVkeHUh?=
KNS-42 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFL3bINKSzVyPU[uO|gyQTdizszN M4XmWnNCVkeHUh?=
GCT MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnlTWM2OD14LkmzPEDPxE1? Ml60V2FPT0WU
DSH1 M1fRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTdwME[zN{DPxE1? NVPhc4hlW0GQR1XS
D-247MG NGTzcolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTHTmZDUUN3ME23MlA4QDhzIN88US=> MnexV2FPT0WU
NCI-SNU-5 NF3O[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TjSGlEPTB;Nz6xPFM4OSEQvF2= MmHlV2FPT0WU
TE-6 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;xO3p6UUN3ME23MlIxPjBzIN88US=> M1;Lc3NCVkeHUh?=
NOMO-1 MorjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\iUYVKSzVyPUeuNlIyOjdizszN NFXMRmpUSU6JRWK=
NB17 NUXMV5BRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHBTWM2OD15LkOwN|A6KM7:TR?= M162[3NCVkeHUh?=
EW-22 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL4TWM2OD15LkO0N|Q5KM7:TR?= MlvFV2FPT0WU
EW-13 M1H2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDvdW5tUUN3ME23MlM2OTZ{IN88US=> NXXoSYRFW0GQR1XS
DOHH-2 NXTCbZBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzGTWM2OD15LkS0NFIh|ryP NYfUboNmW0GQR1XS
TGBC1TKB MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICwOGlKSzVyPUeuOFk5QTlizszN NVm2OpJCW0GQR1XS
GR-ST MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTvTWM2OD15LkWyOVk1KM7:TR?= NFzhN4pUSU6JRWK=
KYSE-520 M2Dmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jlSmlEPTB;Nz61OVUyPSEQvF2= M3fQc3NCVkeHUh?=
CAPAN-1 M1\ORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTdwNUm1NUDPxE1? NEi3S|JUSU6JRWK=
HCE-4 NGDpW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;MUWdxUUN3ME23MlYzOjd7IN88US=> MYnTRW5ITVJ?
MLMA NIfTWGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfEWIJKSzVyPUeuOlI6PTdizszN MXHTRW5ITVJ?
HT-144 MniwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTdwNkWzOlgh|ryP MXnTRW5ITVJ?
KYSE-180 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HyTGlEPTB;Nz63NVE3QSEQvF2= MYLTRW5ITVJ?
TE-5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzmb3FrUUN3ME23Mlk2QTdzIN88US=> MUnTRW5ITVJ?
IGROV-1 MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLDTWM2OD15Lkm4OVUyKM7:TR?= NILUdmJUSU6JRWK=
NCI-H1581 MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFToT3VKSzVyPUiuNFEzKM7:TR?= MVTTRW5ITVJ?
SW1990 MlzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfKOld6UUN3ME24MlA1PjV7IN88US=> M2r5cnNCVkeHUh?=
EFM-19 NUDtdGQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3ZUnJKSzVyPUiuNFg2PDVizszN NEfWe2tUSU6JRWK=
OGR-1 M4rWXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjkdJlxUUN3ME24MlQ{ODJ|IN88US=> M1:0bXNCVkeHUh?=
U-118-MG M3;EWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjNO4h6UUN3ME24MlQ{PDZ|IN88US=> MYPTRW5ITVJ?
SK-OV-3 M2jueGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\yO|BKSzVyPUiuOFY4PjVizszN NWXmbJo4W0GQR1XS
KNS-62 M4jqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnvSJp[UUN3ME24MlUyPzZzIN88US=> MXjTRW5ITVJ?
GOTO MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrpTWM2OD16LkW3OlM2KM7:TR?= MkLzV2FPT0WU
8305C NFPGUI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr3bWlKSzVyPUiuO|A1QDRizszN MVLTRW5ITVJ?
RPMI-2650 NF\lWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr5W4QxUUN3ME24MlcyQTV3IN88US=> MXTTRW5ITVJ?
NEC8 NUjlZWhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP6dIZKSzVyPUiuO|Q{ODdizszN M{XyT3NCVkeHUh?=
KYSE-450 NWLXbJc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHWeFI{UUN3ME24Mlg3PTR6IN88US=> MoLqV2FPT0WU
RMG-I NYixcGo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzGboxKSzVyPUmuNVQxPThizszN MXXTRW5ITVJ?
CAKI-1 NWW4VII3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTzbHJ6UUN3ME25MlMyQTd7IN88US=> MkHPV2FPT0WU
KYSE-510 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4j4WGlEPTB;OT6zOVc4QCEQvF2= MVHTRW5ITVJ?
A4-Fuk NIHRR29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXxTWM2OD17LkO2O|AyKM7:TR?= Ml7MV2FPT0WU
AN3-CA MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzNdZFTUUN3ME25MlQ2PDR2IN88US=> NIDLbnpUSU6JRWK=
SK-N-DZ NFezRlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\MfGlEPTB;OT63Nlg1QSEQvF2= MVLTRW5ITVJ?
HSC-2 M3nmcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLMeXpyUUN3ME25Mlc3PjJ7IN88US=> MnXqV2FPT0WU
EW-1 M2Tacmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPLbm9GUUN3ME25Mlc6OzZ7IN88US=> NWfnOHdSW0GQR1XS
D-566MG NInOZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Pr[GlEPTB;OT64N|Y3PCEQvF2= NVPifmV2W0GQR1XS
COLO-792 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7kTWM2OD17Lkm4O|Q3KM7:TR?= Mnf4V2FPT0WU
TE-10 NFXIcJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrwSFhRUUN3ME2xNE4xOzl4IN88US=> NGTJfXVUSU6JRWK=
NCI-H650 M3:4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLnTWM2OD1zMD60Nlg3KM7:TR?= NITXNIJUSU6JRWK=
U-266 NELJRnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnCNlhkUUN3ME2xNE41PTVizszN M3XYRXNCVkeHUh?=
Detroit562 M4W3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnzdXVKSzVyPUGxMlA2OTVizszN MkPFV2FPT0WU
NH-12 NGT3eopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzidXFKSzVyPUGxMlE1PDZizszN NEL0eGFUSU6JRWK=
CO-314 NGX4V3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFzLkK4OFIh|ryP Mn7DV2FPT0WU
IST-MEL1 NXLafnBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPrboJKSzVyPUGxMlU{OjNizszN M{PxXnNCVkeHUh?=
KNS-81-FD MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFzLkW1Nlch|ryP M2XqdnNCVkeHUh?=
SW1463 Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXMTWM2OD1zMT61PVg6KM7:TR?= NH3hemxUSU6JRWK=
NCI-H23 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXFTWM2OD1zMT62OVUzKM7:TR?= M1jwPXNCVkeHUh?=
SK-MEL-2 NX\4NJZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi4Z3lKSzVyPUGxMlcyQTdizszN M2jn[3NCVkeHUh?=
NB13 NVu3S3pIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fnN2lEPTB;MUKuNVQ6PSEQvF2= MoLSV2FPT0WU
Daoy M4jhXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEOwbmVKSzVyPUGyMlI5PTZizszN MkPOV2FPT0WU
NCI-H1623 Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjJTWM2OD1zMj6zPFAyKM7:TR?= NXnUb5NyW0GQR1XS
NMC-G1 Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m0e2lEPTB;MUKuO|E4KM7:TR?= M1TxV3NCVkeHUh?=
DK-MG NYnHcJZxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF{Lkm0PFIh|ryP M1zRbXNCVkeHUh?=
TCCSUP MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTF|LkGyPFQh|ryP NYW5b|dEW0GQR1XS
SCC-15 M2KycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfhS2xKSzVyPUGzMlI3PTFizszN NGLZe2pUSU6JRWK=
NOS-1 NWfUdlBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTr[W5JUUN3ME2xN{4zQDl|IN88US=> MnzVV2FPT0WU
RH-1 M{PTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF|LkOwN|ch|ryP MljqV2FPT0WU
SK-MEL-3 MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzMcno{UUN3ME2xN{4{PzJ6IN88US=> NFXPXIdUSU6JRWK=
NB5 NYrWcmtET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;mcWlEPTB;MUOuOFA3PyEQvF2= MoPRV2FPT0WU
SNU-387 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Lsd2lEPTB;MUOuOVA4OiEQvF2= M3;NPHNCVkeHUh?=
CAL-120 NV;3WFlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPMT4xSUUN3ME2xN{43PzF6IN88US=> NVLue3JkW0GQR1XS
Mo-T MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPKZ3BuUUN3ME2xN{44ODdizszN MkTEV2FPT0WU
LNCaP-Clone-FGC MnrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnJSHVKSzVyPUGzMlc6QTJizszN MXzTRW5ITVJ?
CAN MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTHOWNKSzVyPUG0MlAzQDhizszN MV3TRW5ITVJ?
SK-MEL-30 NX7uNXVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF2LkC2N{DPxE1? NYSwN5c1W0GQR1XS
COLO-678 NWTiVZk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljzTWM2OD1zND6wPFIzKM7:TR?= M1HzVnNCVkeHUh?=
SCC-9 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nWZWlEPTB;MUSuNVAzOSEQvF2= NIXmO|FUSU6JRWK=
KINGS-1 M4LZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\4OWNKSzVyPUG0MlE1ODJizszN NVywfYpRW0GQR1XS
SL-513 MmLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknSTWM2OD1zND6xPFch|ryP MVLTRW5ITVJ?
HLE NILQWJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z4bWlEPTB;MUSuN|g2OiEQvF2= NV7YUY1zW0GQR1XS
SW1573 M3zVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjCSGRKSzVyPUG0MlQ1OzVizszN NYTVeYRYW0GQR1XS
KYSE-140 NWDtNVlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTF2Lk[zNlch|ryP MkLzV2FPT0WU
SK-PN-DW NFLYd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF2LkiwNFEh|ryP M2nmcHNCVkeHUh?=
A253 M1qycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjwO|RKSzVyPUG1MlA3OjVizszN NHiyZ5NUSU6JRWK=
CAL-12T NY\yXpJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYH6R2FHUUN3ME2xOU41PjZ{IN88US=> M3PJTnNCVkeHUh?=
COLO-679 NInZbWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnntTWM2OD1zNT63Olg{KM7:TR?= M{L1fnNCVkeHUh?=
UACC-257 NVHjWZNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTUTWM2OD1zNj6xNlAyKM7:TR?= NELU[IVUSU6JRWK=
U-87-MG M3XiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnH3TWM2OD1zNj6zOVI{KM7:TR?= M3rUfHNCVkeHUh?=
HCC1806 MlnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrNfpRvUUN3ME2xOk44ODdzIN88US=> MnHMV2FPT0WU
NCI-H2170 NEDufJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTF5LkK0OFgh|ryP M1rnNXNCVkeHUh?=
AGS MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTF5LkO4NFgh|ryP NWWyRVN[W0GQR1XS
MEL-HO MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkD4TWM2OD1zNz63OVA{KM7:TR?= MVXTRW5ITVJ?
SW48 NUDGT|ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzMNo5KSzVyPUG3Mlc4OTZizszN M3yzTnNCVkeHUh?=
HuP-T4 Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHxVZBKSzVyPUG4MlAzODZizszN MXrTRW5ITVJ?
NCI-H720 Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq4TWM2OD1zOD6xOFAzKM7:TR?= NFPk[4lUSU6JRWK=
RCC10RGB MnT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmj0TWM2OD1zOD6xOlk4KM7:TR?= NGD0VGhUSU6JRWK=
HD-MY-Z MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn62TWM2OD1zOD6yNlU1KM7:TR?= NGnNcGlUSU6JRWK=
A427 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrKeHhKSzVyPUG4MlUxQTRizszN MYfTRW5ITVJ?
HCC2998 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Tl[2lEPTB;MUiuOlA2OSEQvF2= NX21UVNlW0GQR1XS
EPLC-272H NI[1bIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qwZ2lEPTB;MUmuNFQ{PCEQvF2= MkHpV2FPT0WU
C32 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfiTWM2OD1zOT6wOFUh|ryP NGf4XYlUSU6JRWK=
UMC-11 MnXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C0VGlEPTB;MUmuNlEzOyEQvF2= M{PEZXNCVkeHUh?=
CaR-1 NUf5SXE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF7Lk[4NFQh|ryP MkPYV2FPT0WU
KYSE-410 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DWemlEPTB;MUmuPVE{QSEQvF2= NISxdoFUSU6JRWK=
HuCCT1 M1vj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofMTWM2OD1{MD62Nlk1KM7:TR?= M1vlVnNCVkeHUh?=
LB996-RCC M3PKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\4RnlKSzVyPUKwMlcyPjhizszN NWi0PYgxW0GQR1XS
KYSE-70 MkG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvmVZhKSzVyPUKwMlgxPTlizszN NX\CPYR7W0GQR1XS
CAL-72 NWjMXGx3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjaTWM2OD1{MD65NVUh|ryP Mn7SV2FPT0WU
Capan-2 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJzLkC0NVMh|ryP NYTYcYFtW0GQR1XS
PANC-08-13 NIn5cmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vw[GlEPTB;MkGuNlUyPSEQvF2= MkTOV2FPT0WU
SBC-1 NIe4d49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3jdXNKSzVyPUKxMlMxQDFizszN NIDNOoxUSU6JRWK=
MFM-223 NGPM[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJzLkOzOFIh|ryP MXHTRW5ITVJ?
BB49-HNC MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmSzTWM2OD1{MT61O|E3KM7:TR?= NXzifo5bW0GQR1XS
SH-4 NXnabWFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYKyU|dvUUN3ME2yNU43PjF6IN88US=> NYDwO2MxW0GQR1XS
HuO9 MmPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHnTWM2OD1{MT65PFI2KM7:TR?= M2TUUnNCVkeHUh?=
AM-38 NUnuc|JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCxTWM2OD1{Mj6wOFg2KM7:TR?= MUTTRW5ITVJ?
A431 M1HMbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTJ|LkKxNVkh|ryP MUjTRW5ITVJ?
YAPC NIix[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;yNmlEPTB;MkOuNlY2OSEQvF2= M3zKWHNCVkeHUh?=
LU-139 NVnmdHQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTJ|LkS4NFkh|ryP MVXTRW5ITVJ?
HEC-1 M4X2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTJ|LkS5N|ch|ryP M3;RZ3NCVkeHUh?=
SCC-25 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXqVHlIUUN3ME2yOE4{ODB4IN88US=> MXLTRW5ITVJ?
HT-29 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zBcGlEPTB;MkSuN|gzOyEQvF2= M1zEVHNCVkeHUh?=
PC-14 M33uOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnm5TWM2OD1{ND62OVcyKM7:TR?= MWDTRW5ITVJ?
Calu-6 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;EV3JqUUN3ME2yOU42ODdzIN88US=> MoLjV2FPT0WU
SJRH30 NH\NOXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\wPINKSzVyPUK1MlY1QTZizszN M{jreHNCVkeHUh?=
ChaGo-K-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTJ4LkG2Nlkh|ryP NUPBcWtFW0GQR1XS
IA-LM NFvOVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLiTWM2OD1{Nj6zOlQ2KM7:TR?= M3fFcXNCVkeHUh?=
GP5d M1XkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;pfWlEPTB;Mk[uOFQ6OSEQvF2= M2\yc3NCVkeHUh?=
NCI-H2291 NYfITmZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jEbWlEPTB;Mk[uOlU1OSEQvF2= MVHTRW5ITVJ?
BALL-1 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLKTWM2OD1{Nj65N|k4KM7:TR?= NEKwVVNUSU6JRWK=
HCC1954 M1vyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ4Lkm4NFgh|ryP M3X5dHNCVkeHUh?=
NCI-H2452 MojPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrSb|VKSzVyPUK3MlQyPjNizszN M{jDSnNCVkeHUh?=
LU-99A MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGGxO3dKSzVyPUK3MlU2QDJizszN NGLNc4RUSU6JRWK=
NTERA-S-cl-D1 MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJ5LkeyPVkh|ryP MYfTRW5ITVJ?
PANC-10-05 M{DvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfVTWM2OD1{Nz63O|c2KM7:TR?= M2W1fXNCVkeHUh?=
NCI-H2405 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mki4TWM2OD1{Nz65N|g4KM7:TR?= MYrTRW5ITVJ?
MDA-MB-415 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLFTWM2OD1{OD60NVM4KM7:TR?= MVPTRW5ITVJ?
NCI-H2342 NWTNeXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnlTWM2OD1{OD61NlgyKM7:TR?= M2H6R3NCVkeHUh?=
TGBC24TKB NXTRUHpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkK5TWM2OD1{OD63NVE4KM7:TR?= M3\VfXNCVkeHUh?=
LU-134-A NGnBUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTJ6LkmyOlEh|ryP M13YNnNCVkeHUh?=
SCC-4 NFjpWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXF[YhKSzVyPUOxMlA1QTRizszN NEHCPZVUSU6JRWK=
Saos-2 NVXKNVYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvyTWM2OD1|MT65N|A3KM7:TR?= M3X1THNCVkeHUh?=
RERF-LC-MS M3TqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPHTWM2OD1|Mj64NlMyKM7:TR?= NXjWS|ZkW0GQR1XS
M14 NH63PIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\aTpZKSzVyPUOyMlk4PjRizszN MmPrV2FPT0WU
HPAF-II M1W2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TqVGlEPTB;M{OuOVAyOSEQvF2= NYrLcXh{W0GQR1XS
NCI-H1755 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP3V5VKSzVyPUO0MlM{ODVizszN MXzTRW5ITVJ?
D-392MG MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\SO5IzUUN3ME2zOU45Pjd2IN88US=> M3rleXNCVkeHUh?=
A704 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTN4LkC0Nlch|ryP M3:0[nNCVkeHUh?=
CP50-MEL-B M1iySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HMU2lEPTB;M{[uNVkyOSEQvF2= NFHETZpUSU6JRWK=
EW-18 NXXHOIRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Xj[mlEPTB;M{[uOFUzKM7:TR?= NYnM[4xoW0GQR1XS
WM-115 MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonVTWM2OD1|Nj64NFk6KM7:TR?= MVfTRW5ITVJ?
LU-65 M{mwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXrJR|UxRTN5LkG0NVch|ryP NGHrb|ZUSU6JRWK=
NCI-H1563 M{X2Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTvTWM2OD1|Nz6yOFg1KM7:TR?= NYPHOotnW0GQR1XS
DBTRG-05MG MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml22TWM2OD1|OD6wOlkyKM7:TR?= M4iydnNCVkeHUh?=
NCI-H630 MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfqeWZKSzVyPUO4MlQ4OTRizszN MVPTRW5ITVJ?
NCI-H1155 NEnNc41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1K2S2lEPTB;M{muNlQzKM7:TR?= NYq2NWVOW0GQR1XS
OVACR-3 NUj0R4YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[5TWM2OD1|OT65NVk2KM7:TR?= NXfQT5N7W0GQR1XS
OAW-42 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfxTWM2OD12MD60NlU5KM7:TR?= MYnTRW5ITVJ?
JVM-2 M2rKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWOw[2RRUUN3ME20NU4zPDF3IN88US=> NIjSSGRUSU6JRWK=
C3A MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTRzLkO0OFch|ryP NX;qfGFHW0GQR1XS
HT55 M2nnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPITWM2OD12Mj6yPFQyKM7:TR?= NFPMW5JUSU6JRWK=
OVCAR-4 Mn\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGr4c3VKSzVyPUSyMlI6PzRizszN MXzTRW5ITVJ?
MEG-01 NUnj[oVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnORWRKSzVyPUSyMlQ3OTZizszN NULNcGVlW0GQR1XS
NCI-H82 M{HyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL4e2dKSzVyPUSzMlk5QTJizszN NX7l[5VJW0GQR1XS
JEG-3 Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTR2Lkm0O{DPxE1? MV7TRW5ITVJ?
BPH-1 Mk[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XybmlEPTB;NE[uN|k6QCEQvF2= NVfEZ2dYW0GQR1XS
MPP-89 NUTrfmpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTR5LkK4PVgh|ryP M2radXNCVkeHUh?=
ALL-PO NFfkZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnpNplmUUN3ME20O{41OTh6IN88US=> MYrTRW5ITVJ?
HT MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTR5LkS5NkDPxE1? MmmzV2FPT0WU
NCI-H2347 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLyWnc{UUN3ME20PE4xPzF3IN88US=> MV;TRW5ITVJ?
A2780 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;R[2lEPTB;NEmuOFIzQCEQvF2= MlHlV2FPT0WU
KARPAS-299 M4LKTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTR7LkWxNVkh|ryP NUXkNGptW0GQR1XS
NCI-H1651 MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPFR5NqUUN3ME20PU45QDJzIN88US=> M2\wN3NCVkeHUh?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
細胞試験:

[1]

+ 展開
  • 細胞株: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • 濃度: 0.01-1 μM
  • 反応時間: 24 hours
  • 実験の流れ:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • 製剤: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • 投薬量: 0-150 mg/kg
  • 投与方法: Given by gavage
    (参考用のみ)

溶解度 (25°C)

体外 Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
Saline
混合させたのち直ちに使用することを推奨します。
20 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 483.99
化学式

C24H29N7O2.HCl

CAS No. 827022-32-2
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

CDKシグナル伝達経路

CDK Inhibitors with Unique Features

相関CDK製品

Tags: Palbociclib (PD-0332991) HClを買う | Palbociclib (PD-0332991) HCl ic50 | Palbociclib (PD-0332991) HCl供給者 | Palbociclib (PD-0332991) HClを購入する | Palbociclib (PD-0332991) HCl費用 | Palbociclib (PD-0332991) HCl生産者 | オーダーPalbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl化学構造 | Palbociclib (PD-0332991) HCl分子量 | Palbociclib (PD-0332991) HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID